The Spleen Tyrosine Kinase (Syk) Regulates Alzheimer Amyloid-β Production and Tau Hyperphosphorylation

Paris D, et al., 289(49):33927-44, J Biol Chem, 2014

The authors have previously reported that the L-type calcium channel (LCC) antagonist nilvadipine reduces brain amyloid-β (Aβ) accumulation. Nilvadipine affects both Aβ production and Aβ clearance across the blood-brain barrier (BBB). Further studies pertaining to the mechanism of action revealed inhibitory effects on spleen tyrosine kinase (Syk) by the Nilvadipine. The Octet RED platform has confirmed the binding and inhibitory effects of Nilvadipine on Syk. A biotinylated version of Syk is loaded onto SSA biosensors to estimate binding with Nilvadipine and BAY61-3606 (positive control). The data identifies Syk as a potential therapeutic target for major pathological lesions that define Alzheimer disease.

Read More